LifeMD(US:LFMD) Globenewswire·2025-10-06 03:20Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [4][6]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses exceeding a certain amount in LifeMD to contact them for legal options [1]. - The firm has set an October 27, 2025 deadline for investors to seek the role of lead plaintiff in a federal securities class action against LifeMD [4]. - The investigation is focused on claims that LifeMD and its executives made false or misleading statements regarding the company's competitive position and financial guidance [6]. Group 2: Financial Performance and Impact - On August 5, 2025, LifeMD reported its second-quarter financial results, revising its revenue guidance to a range of $250 to $255 million, down from a previous estimate of $268 to $275 million [7]. - Following the announcement of the revised guidance, LifeMD's stock experienced a significant decline of 44.8% on August 6, 2025 [7]. Group 3: Class Action Details - The lead plaintiff in a class action is defined as the investor with the largest financial interest who can adequately represent the class [8]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8].